Core Insights - Novo Nordisk's recent study indicated that a new drug did not perform as well as a competitor's product, prompting a downgrade from a sell-side analyst for the first time in five years [1] Company Summary - The downgrade reflects concerns over the efficacy of Novo Nordisk's new drug compared to a rival's offering, which may impact investor sentiment and stock performance [1]

Group 1 - The core point of the article is that Novo Nordisk's experimental obesity drug, developed in collaboration with China's United Laboratories International Holdings, has shown effectiveness in aiding weight loss during a midstage clinical trial conducted in China [1]

Core Insights - Novo Nordisk's triple agonist UBT251 achieved a statistically significant mean weight loss of up to 19.7% after 24 weeks in a trial conducted in China [1][2] - The trial compared three doses of UBT251 (2 mg, 4 mg, and 6 mg) against a placebo in individuals with overweight or obesity [1] Group 1 - The baseline mean body weight of participants was 92.2 kilograms, with the highest mean weight loss observed in the UBT251 group being 19.7%, compared to only 2.0% in the placebo group after 24 weeks [2]

本文源自：金融界AI电报 诺和诺德股价下跌3%，延续周一的跌势。 ...

每经AI快讯，2月24日，诺和诺德股价在分析师调降评级后下跌4%。 ...

巴克莱：将诺和诺德目标价从340丹麦克朗下调至270丹麦克朗。 本文源自：金融界AI电报 ...

巴克莱：将诺和诺德目标价从340丹麦克朗下调至270丹麦克朗。 ...

德意志银行将诺和诺德目标价从400丹麦克朗下调至275丹麦克朗。 ...

花旗集团将诺和诺德目标价从340丹麦克朗下调至309丹麦克朗。 ...

来源：滚动播报 花旗集团将诺和诺德目标价从340丹麦克朗下调至309丹麦克朗。 ...